| Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. | |
| | |
MedLine Citation:
|
PMID: 20544514 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We have retrospectively investigated the effects of three strong statins, atorvastatin, pitavastatin, and rosuvastatin, on serum uric acid (SUA) levels. SUA levels after a few months of statin treatment were compared with those before treatment in 150 outpatients with dyslipidemia. In the atorvastatin (n = 62) and rosuvastatin (n = 45) groups, the SUA levels were reduced by 6.5% (p < 0.0001) and 3.6% (p = 0.03) respectively, but in the pitavastatin group (n = 43), the SUA level increased by 3.7% (p = 0.38). Because uric acid is considered a risk factor for cardiovascular disorders, atorvastatin or rosuvastatin treatment may be recommended when statins are used in patients at high risk for cardiovascular disorders complicated with hyperuricemia. |
| | |
Authors:
|
N Ogata; S Fujimori; Y Oka; K Kaneko |
Related Documents
:
|
6618154 - Chemical structures of angiotensins formed by incubating plasma with the kidney and the... 913024 - Uricosuric effects of niridazole. 15384794 - Effect of icodextrin on transperitoneal uric acid and albumin transport in vitro. 10425354 - Electrostatic charging during a melt agglomeration process. 9573164 - Suppressor scanning at positions 177 and 236 in the escherichia coli lactose/h+ cotrans... 6967504 - The enterohepatic physiology of 24,25-dihydroxyvitamin d3. |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Nucleosides, nucleotides & nucleic acids Volume: 29 ISSN: 1532-2335 ISO Abbreviation: Nucleosides Nucleotides Nucleic Acids Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-06-14 Completed Date: 2010-09-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100892832 Medline TA: Nucleosides Nucleotides Nucleic Acids Country: England |
Other Details:
|
Languages: eng Pagination: 321-4 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, Teikyo University Scool of Medicine, Tokyo, Japan. ogata@med.teiko-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticholesteremic Agents
/
therapeutic use* Cholesterol, LDL / blood Dyslipidemias / blood*, drug therapy* Fluorobenzenes / therapeutic use* Heptanoic Acids / therapeutic use* Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use Pyrimidines / therapeutic use* Pyrroles / therapeutic use* Quinolines / therapeutic use* Sulfonamides / therapeutic use* Uric Acid / blood* |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Cholesterol, LDL; 0/Fluorobenzenes; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrimidines; 0/Pyrroles; 0/Quinolines; 0/Sulfonamides; 110862-48-1/atorvastatin; 147526-32-7/NK 104; 287714-41-4/rosuvastatin; 69-93-2/Uric Acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Establishment and Analysis of SLC22A12 (URAT1) Knockout Mouse.
Next Document: Metabolic syndrome characteristics in gout patients.